N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide

C24H28N2O3

392.49072

-0

MFCD17171361

N-(2,4-二叔丁基-5-羟基苯基)-1,4-二氢-4-氧代-3-喹啉甲酰胺; N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE 是由美国VERTEX公司研发的用于治疗罕见型囊性纤维化的药物,于2012年1月31日经美国食品与药品管理局(FDA)批准上市; 依伐卡托(IVACAFTOR); 依伐卡托; 艾伐卡托; IVACAFTOR (VX-770); VX 770; 依法卡托; N-(2,4-DITERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE;

Ivacaftor; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxaMide; Ivacaftor (VX-770); VX 770, Ivacaftor; Ivacaftor-D4; Kalydeco; 3-QuinolinecarboxaMide, N-[2,4-bis(1,1-diMethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-;

550.4°C/760mmHg

1.187

2~8℃